Bayer - Finerenone - T2DM

Official Title

A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with CKD and T2DM

Study Details

The purpose of this study is to find out if an investigational combination of two drugs is a safe and effective treatment for chronic kidney disease
(CKD) in type 2 diabetes (T2D).

Principal Investigator

Dr. Julie Silverstein

IRB Number



1. Participants must be at least 18 years old
2. Participants must have type 2 diabetes
3. Participants must have chronic kidney disease

Compensation is provided (contact the study team for compensation amount).

Volunteer Information

For more information about this study, contact Volunteer for Health at: